Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2026)

Amylyx Pharmaceuticals' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 6.51% year-over-year to $11.3 million in Q1 2026; TTM through Mar 2026 was $11.3 million, a 6.51% decrease from a year earlier, with the FY2025 full-year figure at $17.9 million, down 25.22% from the prior year.
• Accumulated Expenses fell to $11.3 million in Q1 2026 per AMLX's latest filing, from $17.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $67.9 million in Q1 2024 and bottomed at $3.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $23.9 million (2024), against an average of $30.1 million.
• Across the five-year window, Accumulated Expenses jumped 982.18% in 2023 and sank 82.22% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $38.3 million in 2022, then jumped by 50.67% to $57.7 million in 2023, then sank by 58.51% to $23.9 million in 2024, then fell by 25.22% to $17.9 million in 2025, then plunged by 37.01% to $11.3 million in 2026.
• Per Business Quant, the three latest AMLX Accumulated Expenses figures stand at $11.3 million (Q1 2026), $17.9 million (Q4 2025), and $19.5 million (Q3 2025).